Latest News
Hospitalization Rates Stable, But Diabetes Less Common, Among PAH Patients
Study Suggests PAH Patients Need Special Attention During Intubation
Treprostinil Sodium Has Similar Safety Profiles in Pediatric and Adult PAH
Rare Pancreatic Tumors Could Be a Comorbidity in Patients With PAH
Case Report: Pulmonary Arterial Hypertension Due to Vitamin C Deficiency
PAH May Be a Side Effect of Carfilzomib in Rare Cases
Application for New Imatinib Formulation for PAH Receives Clearance From FDA
Therapeutic Product Candidate Protects Rats Against PAH-Induced Bone Loss
Cardiac Ratio Could Be a New Prognostic Tool for Pediatric PAH
Latest Clinical Trials
Features
Could a Mobile App Boost the Utility of the Six-Minute Walk Test in PAH?
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by vascular proliferation and remodeling of the small pulmonary arteries that ultimately causes right heart failure and premature death. The predominant symptom of PAH is dyspnea on exertion, with a decrease in exercise capacity.1 A variety of methods are available for the objective assessment of…
Israel Emerges as Global Powerhouse in Rare Disease Research
TEL AVIV, Israel — On the 6th floor of Schneider Children’s Hospital in the Tel Aviv suburb of Petah Tikva, 30 children with Alagille syndrome and 2 with lysosomal acid lipase deficiency (LAL-D) receive specialized treatment from a trio of pediatric hepatologists. Across town, at Sheba Medical Center’s Edmond and Lily Safra Children’s Hospital, pediatric…
Study Suggests sRAGE as a Potential Biomarker for Adult PAH
Researchers found that the plasma concentration of soluble receptor for advanced glycation end products (sRAGE) is a sensitive and accurate biomarker for adult pulmonary arterial hypertension (PAH). They concluded that sRAGE “has comparable diagnostic accuracy to the established heart failure biomarker [N-terminal prohormone of brain natriuretic peptide] and shows even better performance in the distinction…
The Prognosis for Patients With PAH Is Improving, but Early Detection Is Key
NEW YORK, New York — Pulmonary arterial hypertension (PAH) is an extremely rare disease, affecting anywhere between 2.0 people per million in the United States to 7.6 per million in Scotland, according to a 2019 review article in European Respiratory Review. In fact, PAH is so rare, says Noah Greenspan, DPT, even many pulmonologists don’t know what to…
NORD Recognizes Progress in Fight Against Rare Disease With 2021 Rare Impact Awards
Under COVID-19’s lingering shadow, the National Organization of Rare Disorders (NORD) has presented its 2021 Rare Impact Awards to 24 pharmaceutical firms, researchers, politicians, and nonprofit groups for their efforts over the past year on behalf of patients with such illnesses. The virtual ceremony was hosted by John Whyte, MD, MPH, chief medical officer at WebMD, with commentary…
PAH Clinical Insights
Exploring Right Ventricular Failure in Pulmonary Arterial Hypertension
We take a deep dive into what we currently understand about right ventricular failure that occurs with pulmonary arterial hypertension.
Targeting the Phenotypic Diversity of Vascular Smooth Muscle Cells to Treat PAH
French researchers have proposed that an overlooked aspect of PAH is the phenotypic diversity of vascular smooth muscle cells (SMCs).
Development of Novel PAH Therapies Focusing on New Pathways
New experimental therapies for pulmonary arterial hypertension promise to target specific molecular pathways associated with the pathophysiology of the disease.
Caring for PAH Patients Amid the COVID-19 Pandemic
Beyond the headlines and in the cold realities of hospital wards, the COVID-19 pandemic has wreaked havoc as physicians scramble to come up with a list of new protocols to manage the influx of highly contagious patients. The COVID-19 pandemic has already upended the neatly divided lines in the hospital wards. In the past, separate…
Rare Care Podcast
Noah Greenspan, DPT, founder of New York City’s Pulmonary Wellness & Rehabilitation Center, runs the nonprofit Pulmonary Wellness Foundation. In this interview, he talks about diagnosing and treating pulmonary arterial hypertension.
PAH Meeting Coverage
- Loading...
Loading...
Loading... 
Loading...